A new study has uncovered an unexpected vulnerability in some of the deadliest cancers. Researchers at UCLA have identified a ...

Adding apalutamide to ADT in the adjuvant and neoadjuvant settings improves outcomes in prostate cancer patients undergoing ...

Perioperative treatment with apalutamide and androgen deprivation therapy (ADT) is beneficial for patients with high-risk ...

CYP2D6 poor metabolizers had ~5-fold higher payload exposure and excess grade ≥3 mucositis, neutropenia, febrile neutropenia, ...

The UK government has unveiled a £20 million funding package to expand a landmark prostate cancer screening trial ...

Weizmann Institute team says blocking a cortisol-driven survival pathway could help overcome resistance to standard hormone therapy.

RASolute 302 showed daraxonrasib reduced mortality risk by 60% versus chemotherapy in previously treated metastatic PDAC, with median OS 13.2 versus 6.7 months. OPTIMA found Prosigna-defined low-risk ...

Doctors followed standard testing guidelines, which recommend discontinuing screenings for men over 70 years old. Should that ...

Lung cancer may not be the most common cancer diagnosis in the United States—that would be prostate cancer for men and breast ...

The largest real-world study ever conducted on prostate cancer in Brazil analyzed data from 670,205 patients treated through ...

Daraxonrasib reduced mortality risk versus chemotherapy in previously treated RAS G12–mutant mPDAC (OS HR 0.40) with fewer discontinuations and delayed pain/QoL deterioration. Perioperative ...

May 31 (Reuters) - Johnson & Johnson's (JNJ.N) ​prostate cancer drug Erleada used with hormone-blocking therapy six months ...